3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
15
Carboplatin
10
Paclitaxel
8
Nivolumab
7
Bevacizumab
6
Gemcitabine
4
Fulvestrant
4
Cisplatin
4
olaparib
3
lenvatinib
3
abemaciclib
3
PM 01183
3
Oxaliplatin
3
Leucovorin
3
Letrozole
3
Docetaxel
3
AZD5305
3
tisotumab vedotin
2
spartalizumab
2
sarilumab
2
sargramostim
2
sacituzumab govitecan
2
ribociclib
2
palbociclib
2
epacadostat
2
enzalutamide
2
dostarlimab
2
cemiplimab
2
anlotinib
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Endometrial Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts